TB-500 Dosage Guide: Complete Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Written by Sam Brooks · Published / Reviewed July 24, 2026

Educational information only — not medical advice. TB-500 is not FDA-approved for any medical use. Every dose, protocol, and chart below is a summary of published research and physician-directed practice, written to inform a conversation with a licensed provider — not a set of self-administration instructions. Peptide therapy at Beverly Hills Rejuvenation Center is physician-supervised. Do not begin, adjust, or stop any peptide protocol without a qualified prescriber.

Quick TB-500 Dosing Summary

In the research literature and in physician-directed practice, TB-500 is most commonly dosed at 2–2.5 mg by subcutaneous injection twice per week during a 4–6 week “loading” phase, then reduced to roughly 2–2.5 mg once every 1–2 weeks for maintenance. Some higher-intensity protocols run 5–7.66 mg per week split across 2–3 injections during loading. These are provider-directed ranges drawn largely from animal research and community practice — not a validated human prescription, because no controlled human trial has ever established a TB-500 dose.

Schedule a Peptide Therapy Consultation →

What Is TB-500?

TB-500 is a synthetic peptide marketed for tissue repair and recovery. It is closely related to thymosin beta-4 (Tβ4), a naturally occurring protein found in nearly every human cell and in high concentration in platelets and wound fluid. Understanding the relationship between “TB-500” and “thymosin beta-4” is the single most important thing to get right about this peptide, because the two names are used interchangeably in marketing but do not refer to the same molecule — and the difference has real consequences for what the evidence actually says.

The Peptide’s Origin and Structure

Full-length thymosin beta-4 is a 43-amino-acid peptide with a molecular weight of roughly 4,963 daltons. It is a major actin-sequestering protein — meaning it binds and regulates actin, the structural protein cells use to move, migrate, and remodel tissue. The product sold as TB-500 is typically not the full 43-amino-acid protein. It is a short synthetic fragment, an acetylated sequence (Ac-LKKTETQ) corresponding to residues 17–23 of thymosin beta-4, with a molecular weight of about 889 daltons. That fragment is the actin-binding “active site” of the parent molecule.

TB-500 vs. Full-Length Thymosin Beta-4 — the Distinction That Matters Most

This is the point most TB-500 write-ups blur, so read it carefully. The peptide you can buy as “TB-500” is, in most cases, the LKKTETQ fragment — the actin-binding heptapeptide — not the complete Tβ4 protein. The full-length protein contains additional functional regions the fragment lacks, most notably the N-terminal Ac-SDKP motif (a separately active tetrapeptide with anti-fibrotic and anti-inflammatory properties). TB-500 retains actin-binding activity but does not carry those other domains.

Why does this matter so much? Because essentially the entire published efficacy literature — the wound, cardiac, and ophthalmic studies people point to when they promote TB-500 — was generated with the full-length Tβ4 protein, not the fragment. When you search the peer-reviewed literature for “TB-500” specifically, you find almost nothing: no completed human clinical trials of the fragment for any indication. The human data that exists — a Phase 1 safety program, Phase 2 dermal wound-healing trials, and Phase 3 ophthalmic trials — was all conducted on full-length thymosin beta-4 (developed pharmaceutically as RGN-259 for the eye and RGN-137 for topical wounds), not on the LKKTETQ fragment sold to consumers. Extrapolating the parent protein’s data onto the fragment is an assumption, not a demonstrated equivalence. Any honest TB-500 guide has to say this out loud, and it shapes how you should read every “benefit” claim below.

How TB-500 Is Thought to Work

The proposed mechanisms are drawn from research on thymosin beta-4 and its actin-binding fragment. In animal and cell-culture models, this pathway is described as promoting cell migration (moving repair cells like fibroblasts and endothelial cells into injured tissue), supporting angiogenesis (new blood-vessel growth), modulating inflammation, and encouraging the kind of tissue remodeling involved in healing. The actin-regulating activity is the throughline: by influencing the cytoskeleton, the peptide is thought to help cells reorganize and move to where repair is needed. It is important to be clear that these are mechanistic findings — largely from the parent protein and largely in animals — not proven clinical effects of the fragment in people.

Why TB-500 Gets So Much Attention

Three features explain the interest. First, its systemic reach: unlike BPC-157, which is often used near a specific injury, TB-500 is promoted as a body-wide recovery peptide, appealing to people with multiple or hard-to-localize issues. Second, its infrequent dosing: because of long tissue persistence, it is dosed a couple of times per week rather than daily, which many find more convenient than daily injections. Third, the halo of the thymosin beta-4 research: the parent protein has a genuinely substantial preclinical and clinical footprint, and that credibility gets borrowed — accurately or not — by the fragment. None of those three features is the same as proven human efficacy for the fragment, and this guide keeps that distinction in view throughout.

What TB-500 Is Not

To set expectations correctly: TB-500 is not an anabolic steroid, a growth hormone, or a growth-hormone secretagogue — it will not directly build muscle or raise IGF-1 the way GH-axis peptides do. It is not a painkiller or an approved anti-inflammatory drug. It is not the same molecule as the thymosin beta-4 used in clinical trials, and it is not an FDA-approved treatment for anything. It is best understood as a research-stage recovery peptide that a physician may consider as an adjunct to — never a replacement for — standard care such as rest, rehabilitation, physical therapy, and appropriate medical treatment.

TB-500 Dosing Protocols Based on Clinical Research

There is no FDA-approved dose of TB-500 because there is no FDA-approved TB-500 product, and — as emphasized above — no completed human trial of the fragment to anchor to. The ranges below are synthesized from thymosin beta-4 preclinical work, allometric scaling from animal studies, and how physician-supervised clinics translate that into practice. They are provider-directed education, not a protocol to run on your own.

The Loading-and-Maintenance Model

TB-500 is almost always described with a two-phase structure. A loading phase uses higher, more frequent dosing to build tissue levels, followed by a maintenance phase with reduced dosing to sustain the effect. This is different from BPC-157, which is typically dosed daily throughout a cycle. The loading/maintenance framing is a direct consequence of TB-500’s long tissue persistence: because it is not cleared quickly, twice-weekly loading and every-1-to-2-week maintenance are enough to keep it present.

Standard Dosing Ranges

The most frequently cited approach is 2–2.5 mg subcutaneously, twice per week, for 4–6 weeks during loading, then 2–2.5 mg once every 1–2 weeks for maintenance. Note the units: TB-500 is dosed in milligrams, not the micrograms used for BPC-157 — a practical difference that changes the syringe math substantially (covered below). Higher-intensity protocols cited in the community run up to 5–7.66 mg per week during loading, split across 2–3 injections; these larger totals are provider-directed and not better-evidenced, just larger.

Beginner, Intermediate, and Advanced Tiers

The table below frames conservative through higher-intensity approaches as tiers. For someone new to the peptide, the conservative tier — a lower weekly total, assessed for tolerance — is the sensible starting point.

Indication-Specific Dosing: Tendon, Ligament & Muscle

TB-500 is most searched for musculoskeletal recovery — tendon, ligament, and muscle injuries. Unlike BPC-157, TB-500 is generally dosed systemically rather than injected near the injury, on the rationale that its promoted mechanism (cell migration into damaged tissue) works body-wide and that the peptide distributes to sites of injury on its own. A representative practical framing:

The rodent and cell-culture evidence base for actin regulation and cell migration is where thymosin beta-4 has been studied most; human data for the fragment in these musculoskeletal uses is effectively absent, as discussed under Clinical Trial Data.

Indication-Specific Dosing: Systemic Recovery & Inflammation

Beyond discrete injuries, TB-500 is used with a general recovery or anti-inflammatory intent — for example alongside a demanding training block, or during recovery from broader overuse. Dosing does not change meaningfully from the standard loading/maintenance ranges; what changes is the goal and the monitoring. Because the effect (if any) is systemic and slow, this use is best framed as a defined course tied to a recovery window, not an open-ended supplement.

How Body Weight and Injury Severity Factor In

Much of the dosing rationale derives from weight-scaled animal work, so body weight is one lever a provider may consider: a larger patient sits nearer the top of the range (2.5 mg, or the higher weekly totals), a smaller patient nearer the bottom (2 mg). Injury severity and acuity are the second lever — a significant, fresh injury may be loaded at the higher, more frequent end for a defined window, while a maintenance goal is kept minimal. The consistent theme is start conservative, reassess, and escalate only with a reason, because no human trial has defined an “optimal” dose to anchor to.

Research-Based Protocols and Allometric Scaling

Many of the human dose ranges in circulation are derived by allometric scaling from thymosin beta-4 animal studies, then rounded to convenient milligram amounts. Scaling is an approximation, not a validated human dose — and it compounds an already shaky assumption, since the animal efficacy work largely used the full-length protein rather than the LKKTETQ fragment. This double gap (animal-to-human, and full-length-to-fragment) is exactly why the field emphasizes conservative dosing and physician supervision.

Clinical Trial Data and the Human Evidence Gap

Honest evidence framing matters here more than almost anywhere in peptide therapy, and TB-500 is a case where the marketing and the data are the furthest apart. There are no completed randomized controlled trials of the TB-500 fragment in humans for any indication. The human clinical program that people cite belongs to full-length thymosin beta-4: a Phase 1 safety program established tolerability of intravenous Tβ4; Phase 2 topical trials (RGN-137) studied dermal wounds such as pressure ulcers, venous stasis ulcers, and epidermolysis bullosa; and Phase 3 ophthalmic trials (RGN-259) tested a Tβ4 eye drop for neurotrophic keratopathy and dry eye. Even that full-length program has produced mixed results — a European Phase 3 neurotrophic keratitis trial (SEER-3) missed its primary endpoint, attributed to a strong placebo effect. In short: the parent-protein story is real but uneven, and the fragment sold as TB-500 has essentially no human efficacy evidence of its own. Treat every benefit claim you read as an extrapolation until fragment-specific human trials exist.

Talk to a BHRC physician about whether TB-500 fits your situation →

How to Reconstitute TB-500

TB-500 is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before it can be measured or injected. The following is educational reference material describing how reconstitution works; in a physician-supervised setting, mixing and dosing are prepared or directed by clinical staff.

What You Need

• A vial of lyophilized TB-500 (commonly 5 mg; also sold as 10 mg)
• Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol as a preservative
• A reconstitution syringe (e.g., 3 mL) and a U-100 insulin syringe for dosing
• Alcohol swabs and a clean surface

Step-by-Step Reconstitution

1. Sanitize. Wash hands; wipe both vial stoppers (peptide and BAC water) with alcohol swabs and let dry.
2. Draw the diluent. Draw your chosen volume of bacteriostatic water into the reconstitution syringe (for a 5 mg vial, 2 mL is a common, easy-math choice giving 2.5 mg/mL).
3. Add slowly. Insert the needle into the peptide vial and let the water run slowly down the inside wall of the vial — do not spray it directly onto the powder.
4. Dissolve gently. Swirl gently; do not shake. The powder should dissolve into a clear solution within a minute or two.
5. Refrigerate. Store the reconstituted vial at 2–8°C.

Reconstitution Math Done For You (5 mg and 10 mg Vials)

Concentration is simply the total peptide divided by the total water you added. Because TB-500 doses are in milligrams — much larger than BPC-157’s micrograms — the injection volumes are correspondingly larger, so the amount of water you choose matters a lot for how comfortable the injection is. The table below does the math for the most common combinations on both vial sizes.

Key relationship to remember: On a U-100 insulin syringe, “units” are hundredths of a milliliter (100 units = 1 mL). So at 5 mg/mL, 40 units (0.4 mL) delivers 2 mg; at 2.5 mg/mL, you need 80 units (0.8 mL) for the same 2 mg. Using less water (a higher concentration like 5 mg/mL) keeps the injection volume small and is often the more comfortable choice for TB-500.

Dosing Calculation Examples (Syringe-Unit Chart)

Using the brief’s reference setup — a 5 mg vial reconstituted with 2 mL BAC water (2.5 mg/mL) — here is exactly how far to draw the plunger on a U-100 insulin syringe for each target dose:

At 2.5 mg/mL a 5 mg vial provides two 2.5 mg doses (or a couple of 2 mg doses with a little left over). Notice that a 2.5 mg dose fills an entire 1 mL U-100 syringe — this is why many people prefer the higher-concentration 5 mg/mL mix (5 mg vial + 1 mL, or 10 mg vial + 2 mL), which puts a 2 mg dose at a comfortable 40 units.

Why TB-500 Injection Volumes Are Larger Than BPC-157

This trips people up when they cross over from a BPC-157 protocol. BPC-157 is dosed in micrograms (250–500 mcg), so a dose is a tiny 10–20 units. TB-500 is dosed in milligrams (2,000–2,500 mcg), roughly 5–10× larger by mass, so the same concentration produces a much larger injection volume. The two practical fixes are to (1) reconstitute at a higher concentration to keep the volume down, and (2) split a very large loading dose into two injections at different sites. A provider will typically pick the concentration that keeps the routine dose in a single, comfortable subcutaneous injection.

Common Reconstitution Mistakes

• Confusing milligrams with micrograms. This is the most dangerous TB-500-specific error. A dose is “2 mg,” which is 2,000 mcg — do not treat it like a BPC-157 microgram dose. Mixing up mg and mcg by a factor of a thousand is a catastrophic dosing error.
• Forgetting that the concentration determines the units. The same “80 units” delivers 2 mg at 2.5 mg/mL but 4 mg at 5 mg/mL. Always match your syringe chart to the exact amount of water you added.
• Using sterile water instead of bacteriostatic water. Plain sterile water has no preservative and shortens usable shelf life; bacteriostatic water (0.9% benzyl alcohol) is the standard diluent for multi-day vials.
• Spraying water onto the powder or shaking the vial. Peptides are delicate; add water down the wall and swirl gently rather than shaking.

In a physician-supervised program these steps are handled or verified by clinical staff, which removes most of this error surface — one of the practical arguments for supervised use over DIY.

Storage and Shelf Life

Lyophilized (unmixed) TB-500 is generally stored frozen or refrigerated and is stable for many months. Once reconstituted, keep it refrigerated at 2–8°C and use it within roughly 28–30 days — the benzyl alcohol in bacteriostatic water preserves the solution for about that long. Keep it out of light, never freeze a reconstituted vial, and discard if the solution becomes cloudy or discolored. Because TB-500 is dosed only a couple of times per week, a single reconstituted vial may last several weeks of a cycle, so plan the vial size and concentration against that ~30-day window to avoid wasting peptide.

TB-500 Administration Guide

The following describes standard subcutaneous injection technique for educational reference. In a physician-supervised program, technique is taught and overseen by clinical staff.

Injection Site Selection

TB-500 is generally given systemically, so the subcutaneous fat of the abdomen (a couple of inches away from the navel) is the most common site, with the outer thigh and back of the arm as alternatives. Rotate sites to avoid irritation. Because TB-500 injection volumes can be relatively large, some people prefer the abdomen or thigh where there is more subcutaneous tissue to accommodate the volume comfortably.

Subcutaneous Injection Technique

1. Wipe the chosen site with an alcohol swab and let it dry.
2. Pinch a fold of skin to lift the subcutaneous fat away from muscle.
3. Insert the insulin needle at a 45–90° angle into the fold.
4. Depress the plunger slowly and steadily to deliver the measured dose — inject slowly, as larger volumes go in more comfortably when not rushed.
5. Withdraw, apply gentle pressure with a clean swab, and dispose of the needle in a sharps container.

Systemic vs. Near-Injury Injection

A common question is whether TB-500, like BPC-157, should be injected near an injury. For TB-500 the usual answer is no — it is typically dosed systemically, on the rationale that its promoted mechanism (cell migration and systemic distribution to sites of damage) does not depend on local placement. This is one of the practical differences between the two peptides in the “Wolverine stack,” and it is why they are often paired: BPC-157 used with a local intent, TB-500 used systemically. There is no human trial validating either placement strategy.

Injection Comfort and Reducing Bruising

Small habits reduce the most common nuisance, injection-site bruising: use a fresh, fine-gauge insulin needle each time; let the alcohol dry fully before inserting; avoid visible surface veins; inject slowly; and apply brief, gentle pressure afterward rather than rubbing. Because TB-500 volumes are larger, rotating sites is especially important — alternating sides of the abdomen or between abdomen, thigh, and arm — to prevent local irritation from building up over a multi-week cycle. If a site becomes persistently sore, red, warm, or swollen, that is a reason to pause and contact your provider rather than to keep injecting the same spot.

Optimal Timing for TB-500 Administration

Loading-Phase Frequency

During loading, TB-500 is typically given twice per week (for example, Monday and Thursday) to keep dosing spread across the week. Higher-intensity protocols may split a larger weekly total into 2–3 injections. The exact days matter less than keeping them reasonably spaced and consistent from week to week. In maintenance, a single injection every 1–2 weeks is typical.

Timing Around Training and Injury

TB-500 is not strongly food-dependent, so many people pick fixed days for adherence. For injury or training contexts, some practitioners time doses within a recovery block, but there is no strong human evidence that a specific clock time or training-relative timing improves outcomes. Because the peptide persists in tissue for days, the loading/maintenance schedule — not the hour of the day — is what governs exposure.

TB-500 Cycle Length and Protocol Duration

Typical Cycle Lengths

A TB-500 cycle is commonly structured as a 4–6 week loading phase followed by an optional maintenance phase of similar or longer length at reduced frequency, with total active use often kept to around 6–12 weeks before a break. Longer continuous use is generally discouraged without a clear clinical reason and provider oversight — in part because of the theoretical angiogenesis concern discussed below, and in part because there is simply no long-term human safety data for the fragment.

Cycling On and Off

Most protocols build in an off-cycle rather than running TB-500 continuously. The intent is to use it as a defined course tied to a healing or recovery goal, evaluate the result, and stop — not to take it indefinitely. Whether and when to repeat a cycle is a provider decision informed by response and any monitoring.

What “Finishing a Cycle” Should Look Like

A well-run cycle has a defined endpoint decided in advance, not an open-ended “keep going until the vial runs out.” Practically, that means agreeing with your provider on the goal (for example, resolving a specific tendon issue), the loading length and maintenance plan, and the checkpoint at the end where you assess whether the goal was met. If it was, you stop and reassess later; if it was not, that is important information — it may mean TB-500 is not doing what you hoped, that the underlying problem needs a different intervention, or that further medical evaluation is warranted. Treating the peptide as a permanent supplement is precisely the pattern supervised programs try to avoid, both because of the theoretical angiogenesis concern and because indefinite use of an unproven agent is hard to justify.

TB-500 Safety Profile and Potential Side Effects

Because human data on the fragment is essentially absent, the honest summary is: TB-500 has been reported to be well tolerated at the doses used, and the full-length thymosin beta-4 program found intravenous Tβ4 to be safe in early trials — but the fragment’s safety is not established by controlled human trials, and there is no long-term human safety record at all.

Commonly Reported Side Effects

• Injection-site reactions — redness, mild pain, bruising, or swelling (more likely given the larger injection volumes)
• Transient fatigue, lightheadedness, or head-rush reported anecdotally, especially early in loading
• Temporary flu-like feeling or lethargy reported by some users during loading
• Occasional nausea or headache

These are largely anecdotal; the absence of controlled fragment trials means the true side-effect profile is not well characterized.

The Theoretical Cancer / Angiogenesis Concern

This concern deserves a direct answer rather than being buried. TB-500’s proposed benefits work partly through promoting cell migration and angiogenesis — the growth of new blood vessels and the movement of cells into tissue. Those same processes are ones that tumors exploit to grow and spread (angiogenesis to build a blood supply, migration in metastasis). That biological overlap is the basis of a legitimate theoretical question: could a pro-migratory, pro-angiogenic peptide, in principle, support the growth or spread of an existing or occult cancer?

What the evidence actually shows: no study has demonstrated that TB-500 causes cancer in humans, and there is no human data quantifying any cancer risk. The concern is mechanistic and plausible, not demonstrated. The prudent, physician-supervised stance is straightforward: TB-500 is generally avoided in anyone with an active malignancy, a recent cancer history, or undiagnosed suspicious symptoms, and its pro-migratory/pro-angiogenic profile is precisely why open-ended, unsupervised use is discouraged. If you have any cancer history, this is a conversation to have explicitly with your physician before considering TB-500.

Contraindications

• Active or recent cancer, or undiagnosed suspicious symptoms (see angiogenesis/migration discussion above)
• Pregnancy and breastfeeding (no safety data; promotes cell migration and angiogenesis)
• Known hypersensitivity to the peptide or to benzyl alcohol (in bacteriostatic water)
• Competitive athletes subject to anti-doping testing (WADA-prohibited — see regulatory section)

Drug and Supplement Interactions

Formal interaction studies do not exist for TB-500. The area warranting the most provider attention is any angiogenesis-modulating therapy (including certain cancer treatments), where the peptide’s pro-angiogenic activity could be biologically relevant, and any situation involving abnormal cell growth. Always give your provider a full medication and supplement list, including other peptides, before starting.

Combining TB-500 with Other Peptides and Therapies

TB-500 is most famous as half of a stack. The pairing has a nickname, and it comes up constantly in patient questions.

The BPC-157 + TB-500 “Wolverine Stack”

The “Wolverine stack” is a community nickname for combining BPC-157 with TB-500, both of which have been studied for soft-tissue repair. The rationale is complementary intent: BPC-157 is often used with a local focus near an injury and dosed daily, while TB-500 is used systemically and dosed a couple of times per week for its proposed effects on cell migration and inflammation. It is not a branded drug, not a standardized clinical protocol, and not FDA-approved — and no controlled human study has evaluated the combination. We cover the pairing in depth in our dedicated BPC-157 + TB-500 Wolverine Stack dosage guide.

Wolverine Stack Dosing

Treat these numbers as an orientation to the conversation, not a protocol to self-run. Note the very different dosing rhythms: BPC-157 is a daily microgram dose, TB-500 is a twice-weekly milligram dose — so on most days of a stack, only BPC-157 is being injected.

Can BPC-157 and TB-500 Be Mixed in One Syringe?

A frequent practical question is whether the two Wolverine-stack peptides can be drawn into the same insulin syringe to reduce injections. In practice some people do combine them for convenience on the days both are dosed, but this is a decision for your provider — it affects nothing about the individual doses, only the number of injections, and it presumes both are reconstituted and compatible. It is also complicated by volume: a full TB-500 dose can already fill much of a 1 mL syringe, leaving little room. When in doubt, injecting them separately removes any ambiguity about how much of each was delivered.

Other Common Pairings

TB-500 is sometimes discussed alongside growth-hormone-axis peptides for a recovery-and-body-composition emphasis, such as CJC-1295 / Ipamorelin or Tesamorelin, and alongside mitochondrial-oriented peptides like MOTS-c. Any stack multiplies the unknowns and should be built by a physician, not assembled from forums. A key principle when stacking: change one variable at a time, so a benefit — or a side effect — can be attributed to the right agent.

Peptide Comparison Matrix

Who Should Consider TB-500 Therapy?

Potential Candidates

In a physician-supervised setting, people who ask about TB-500 are often dealing with a stubborn or diffuse soft-tissue injury (tendon, ligament, muscle), recovery from heavy training, or general recovery goals, and want to understand a research-adjacent adjunct alongside standard care. The most appropriate candidate is someone who understands the evidence is early and fragment-specific data is absent, wants medical oversight, and has no contraindications.

Who Should Avoid It

• Anyone with active, recent, or suspected cancer
• People who are pregnant or breastfeeding
• Competitive athletes subject to WADA/USADA testing
• Anyone unwilling or unable to use it under physician supervision
• People expecting a proven, FDA-approved treatment — TB-500 is not that

Monitoring Progress and Adjusting Protocols

What to Track

Because there is no validated biomarker for TB-500, monitoring is primarily clinical and functional: pain, range of motion, and function, tracked across the cycle. A provider may also monitor for any side effects and review overall health status. Keep a simple log of dose, site, date, and how you feel — this is especially useful with a twice-weekly schedule where it is easy to lose track of which day a dose was given.

When to Adjust or Stop

Reasons to pause and consult your provider include no meaningful improvement by the end of a loading phase, any concerning or persistent side effect, or any new symptom that warrants evaluation before continuing. Dose changes should be provider-directed, not self-titrated.

Setting Realistic Expectations

Two expectation traps are worth naming. The first is the “miracle recovery peptide” framing that circulates online — the reality is that human efficacy for the fragment is unproven, and TB-500 is best thought of as a possible adjunct with an uncertain effect size, not a guaranteed fix. The second is impatience: soft-tissue healing takes weeks under the best circumstances, and a loading phase is 4–6 weeks by design, so judging it after a few doses is not meaningful. Give a provider-directed cycle its full defined length before concluding it did or did not help, and measure against functional milestones (less pain, more range of motion, return to activity) rather than day-to-day feel.

TB-500 Half-Life and Detection Time

How Long It Stays Active

TB-500’s dosing rhythm — twice weekly rather than daily — reflects its long tissue persistence. While the parent thymosin beta-4 protein has a relatively short circulating half-life, the actin-binding fragment is described as persisting in tissue long enough that infrequent dosing maintains exposure. This is the pharmacologic reason the loading/maintenance model works: you are not chasing a rapidly clearing drug, so a couple of injections a week suffice during loading and every 1–2 weeks suffices for maintenance.

Detection Window for Tested Athletes

For anyone subject to anti-doping testing, the practical number to know is the detection window of roughly 30–45 days after administration. WADA-accredited laboratories detect thymosin beta-4 and TB-500 by liquid chromatography–tandem mass spectrometry (LC-MS/MS) at very low concentrations, and advanced testing can identify metabolites for longer periods. Because TB-500 is prohibited at all times (in and out of competition), and because sanctions run from two to four years, a long detection window means there is effectively no “safe” time to use it for a tested athlete. This is covered further in the regulatory section below.

Is TB-500 FDA-Approved? Legal & Regulatory Status (2026)

The short answer, dated: as of July 24, 2026, TB-500 has no FDA approval for any medical indication. Its regulatory status has been in motion through 2026, so the details below are stated as a dated snapshot — nothing here means TB-500 is “now approved” or “now legal to freely buy.”

FDA Compounding Status: The 2023–2026 Timeline

What the July 2026 PCAC Decision Actually Means

This is the most important — and most misread — point in the whole topic. The April 2026 removal from Category 2 was not an approval; it happened largely because the parties who nominated TB-500 for compounding withdrew their nomination, which moved the substance into an evaluative limbo rather than onto the market. Then, at the July 23, 2026 PCAC meeting, the FDA went further and proposed that TB-500 (both free base and acetate) NOT be added to the 503A bulk-substances list. The agency’s stated reasons were pointed: it found no human effectiveness data, cited an in-vitro study in which TB-500 did not induce wound healing in fibroblast cultures, and concluded that neither form is adequately physically and chemically characterized (noting inconsistent naming across INN/USAN/IUPAC conventions and missing characterization data). In plain terms: rather than moving toward legitimizing compounded TB-500, the 2026 process moved against it. Anyone telling you 2026 made TB-500 “legal to buy and use like a medication” has the story backwards.

DEA and Athletic (WADA) Status

TB-500 is not a DEA-scheduled controlled substance — it is not a narcotic and possession is not a criminal-scheduling matter. However, it is prohibited in sport by the World Anti-Doping Agency (WADA) at all times, in and out of competition. TB-500 and thymosin beta-4 fall under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of the WADA Prohibited List, within the growth factors category, and are treated as non-specified substances. Any athlete subject to WADA or USADA testing should treat TB-500 as a banned substance; with a 30–45 day detection window and two-to-four-year sanctions, there is no window in which use is compatible with testing. TB-500’s ambiguous compounding status does not create any anti-doping exemption.

Why “Research Use Only” Products Are a Warning Sign, Not a Loophole

Much of the TB-500 sold online is labeled “for research use only” and “not for human consumption.” That label is a regulatory and quality warning, not a wink-and-nod formality. It means the product has not been manufactured, tested, or verified to the standards required for anything a person injects, and there is no guarantee of identity, purity, sterility, or dose accuracy — a concern the FDA itself echoed in 2026 when it flagged how poorly characterized TB-500 products are. Contamination, under- or over-dosing, mislabeled contents, and even sequence ambiguity (fragment vs. full-length) are real risks in the gray-market supply chain. This is a core reason BHRC’s position is physician-supervised care rather than self-sourced peptides: supervision addresses not only dosing and candidacy but the fundamental question of what is actually in the vial.

Beverly Hills Rejuvenation Center does not sell raw or “research-use” peptides and does not provide TB-500 for unsupervised use. Regulatory status is changing; the summary above is accurate as of July 24, 2026 and should be re-verified over time.

Conclusion

TB-500 is one of the most popular recovery peptides — and one of the most overstated. The dosing conventions are reasonably consistent (2–2.5 mg twice weekly during a 4–6 week loading phase, then 2–2.5 mg every 1–2 weeks for maintenance), and the reconstitution math is simple once you respect that TB-500 is a milligram-dosed peptide, not a microgram one (a 5 mg vial in 2 mL of water gives 2.5 mg/mL, so 2 mg is 80 units). But the honest headline is the evidence gap: the product sold as TB-500 is a fragment of thymosin beta-4, it has zero completed human trials of its own, the human data belongs to the full-length protein (with mixed results), and its 2026 U.S. regulatory trajectory moved against compounding rather than toward approval. That combination — plus the theoretical migration/angiogenesis concern — is exactly why TB-500 belongs in a supervised medical conversation, where dose, candidacy, monitoring, and risk can be weighed for you specifically.

Schedule a Peptide Therapy Consultation with a BHRC physician →

Frequently Asked Questions About TB-500 Dosing

What is the standard TB-500 dosage?

The most commonly cited approach is 2–2.5 mg by subcutaneous injection twice per week during a 4–6 week loading phase, then roughly 2–2.5 mg once every 1–2 weeks for maintenance. Some protocols use higher weekly totals (5–7.66 mg/week) split across 2–3 injections during loading. These are provider-directed ranges drawn from animal research and community practice, not a validated human prescription — no controlled human trial of TB-500 has ever established a dose.

How do I reconstitute a 5 mg TB-500 vial and how many units is 2 mg?

A common approach is adding 2 mL of bacteriostatic water to a 5 mg vial, giving 2.5 mg/mL. At that concentration, 2 mg equals 0.8 mL, which is 80 units on a U-100 insulin syringe, and 2.5 mg equals 1.0 mL (a full 100-unit syringe). Many people instead use less water (5 mg + 1 mL = 5 mg/mL) so a 2 mg dose is a smaller 40 units. In a supervised program, mixing and measuring are prepared or directed by clinical staff.

What is the difference between TB-500 and thymosin beta-4?

They are marketed interchangeably but are not the same molecule. Thymosin beta-4 is the full 43-amino-acid protein; TB-500 is typically a short synthetic fragment (Ac-LKKTETQ, the actin-binding region), which lacks other domains of the parent such as the anti-fibrotic Ac-SDKP motif. Crucially, essentially all the human clinical data belongs to the full-length protein, not the fragment sold as TB-500 — so benefit claims for TB-500 are extrapolations.

What is the difference between the loading phase and maintenance phase?

The loading phase uses higher, more frequent dosing (about 2–2.5 mg twice weekly for 4–6 weeks) to build tissue levels. The maintenance phase then drops to about 2–2.5 mg every 1–2 weeks to sustain the effect. This two-phase model works because TB-500 persists in tissue for days, so infrequent dosing maintains exposure.

How long should a TB-500 cycle last?

A typical cycle is a 4–6 week loading phase, optionally followed by a maintenance phase, with total active use often kept to around 6–12 weeks before a break. Continuous long-term use is generally discouraged without a clear clinical reason and physician oversight, partly because of the theoretical migration/angiogenesis concern and partly because there is no long-term human safety data for the fragment.

What are the benefits of TB-500?

TB-500 is studied and promoted for soft-tissue recovery — tendon, ligament, and muscle repair — and for general recovery, based on its actin-regulating, cell-migration, and angiogenic activity in preclinical models. Be careful with these claims: they come mostly from research on the full-length thymosin beta-4 protein and from animal studies, and there are no completed human trials of the TB-500 fragment demonstrating these benefits.

What are the side effects of TB-500?

Reported side effects are mostly mild and anecdotal: injection-site redness or bruising (the larger injection volume makes this more likely), transient fatigue, head-rush, a temporary flu-like feeling during loading, or occasional nausea or headache. Because there are no controlled human trials of the fragment, the true side-effect profile is not well characterized, and there is no long-term human safety record.

What is the BPC-157 and TB-500 “Wolverine stack” dose?

A representative framing is BPC-157 at 250–500 mcg/day (often local, near an injury) combined with TB-500 dosed systemically — about 2–2.5 mg twice weekly during loading, then roughly 2–2.5 mg every 1–2 weeks for maintenance. It is a community nickname, not an FDA-approved or clinically validated protocol, and no controlled human study has evaluated the combination. It should only be considered under physician supervision.

How long does TB-500 stay in your system for a drug test?

The commonly cited detection window is roughly 30–45 days after administration, with advanced mass-spectrometry testing potentially identifying metabolites for longer. TB-500 and thymosin beta-4 are prohibited at all times by WADA (Section S2, growth factors), and sanctions run from two to four years, so there is effectively no safe window for a tested athlete to use it.

Is TB-500 FDA-approved or legal in 2026?

As of July 24, 2026, TB-500 has no FDA approval for any indication. The FDA placed it in 503A Category 2 in September 2023, removed it from Category 2 in April 2026 (after nominators withdrew the nomination), and at the July 23, 2026 Pharmacy Compounding Advisory Committee meeting proposed NOT to add it to the 503A bulks list, citing no human effectiveness data and inadequate characterization. It is not a DEA-scheduled substance but is prohibited in sport by WADA. This status is evolving and should be re-verified.

Related Resources from BHRC

• Schedule a Peptide Therapy Consultation — physician-supervised peptide programs at BHRC
• BPC-157 Dosage Guide — the daily-dosed companion peptide, and the other half of the Wolverine stack
• BPC-157 + TB-500 Wolverine Stack Dosage Guide — the combined protocol in depth
• CJC-1295 / Ipamorelin — growth-hormone-axis peptide often discussed for recovery and body composition
• Tesamorelin — GHRH analog studied for body composition
• MOTS-c — mitochondrial-derived peptide studied for metabolism and exercise capacity

References

1. Sosne G, et al. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. PMCID: PMC9820614. Read on PMC [PMCID from search index — verify before publish.]
2. Sosne G, et al. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. Scientific Reports. 2018;8:10500. doi:10.1038/s41598-018-28861-5. View article
3. Cavasin MA, et al. Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis. PMCID: PMC5085123. Read on PMC [PMCID from search index — verify before publish.]
4. Goldstein AL, Kleinman HK, et al. Thymosin β4 wound-healing, tissue-regeneration, and actin-regulation mechanism reviews. [Multiple papers; specific PMIDs pending verification — see internal TODO.]
5. RegeneRx Biopharmaceuticals. RGN-137 (topical thymosin β4) Phase 2 dermal wound-healing trials (pressure ulcers, venous stasis ulcers, epidermolysis bullosa). [Trial identifiers pending verification — see internal TODO.]
6. HLB Therapeutics / RegeneRx. SEER-3 Phase 3 neurotrophic keratitis trial of RGN-259 — primary endpoint not met (trade-press report). [Verify against primary source before publish.]
7. U.S. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Pharmacy Compounding Advisory Committee materials on TB-500 (free base and acetate), meeting July 23, 2026; FDA proposed non-inclusion on the 503A bulks list.
8. World Anti-Doping Agency. 2026 Prohibited List — Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), growth factors category.

About the Author & Medical Reviewer

Sam Brooks is a health and wellness content writer for Beverly Hills Rejuvenation Center, specializing in evidence-based peptide and regenerative-medicine education.

About the medical review: This guide was reviewed by the clinical team at Beverly Hills Rejuvenation Center — board-certified physicians and licensed medical providers who oversee BHRC’s medical protocols and review its clinical education for accuracy, safety, and compliance. Reviewed July 24, 2026. This content is educational and does not replace an individual medical evaluation; peptide therapy at BHRC is physician-supervised.